<!--StartFragment-->RESULT 1
AAY05069
ID AAY05069 standard; protein; 205 AA.
XX
AC AAY05069;
XX
DT 16-JUN-1999 (first entry)
XX
DE Human PIGR-2 protein sequence.
XX
KW PIGR-2; human; autoimmune disease; rheumatoid arthritis; psoriasis;
KW Multiple Sclerosis; Systemic Lupus Erythematosus; diagnosis; therapy;
KW Inflammatory Bowel Disease.
XX
OS Homo sapiens.
XX
PN EP905237-A2.
XX
PD 31-MAR-1999.
XX
PF 07-AUG-1998; 98EP-00306323.
XX
PR 25-AUG-1997; 97US-0056774P.
PR 21-NOV-1997; 97US-00976293.
XX
PA (SMIK) SMITHKLINE BEECHAM CORP.
XX
PI Sweet RW, Truneh A, Wu S;
XX
DR WPI; 1999-192665/17.
DR N-PSDB; AAX28250.
XX
PT New polypeptides encoding human PIGR-2 useful for treating diseases such
PT as rheumatoid arthritis and multiple sclerosis.
XX
PS Claim 11; Page 17; 23pp; English.
XX
CC This sequence is the human PIGR-2 protein of the invention. Autoimmune
CC diseases involving altered expression or activity of PIGR-2 may include
CC rheumatoid arthritis, Multiple Sclerosis, psoriasis, Systemic Lupus
CC Erythematosus and Inflammatory Bowel Disease. These diseases can be
CC diagnosed or susceptibility to them predicted by: (1) determining whether
CC there is a mutation in the genomic copy of the gene encoding PIGR-2; or
CC (2) measuring the amount of PIGR-2 in a sample derived from the patient.
CC Patients deficient in PIGR-2 can be treated by administering either the
CC PIGR-2 DNA or its complement or an agonist of PIGR-2 to the patient.
CC Patients with excessive expression or activity of PIGR-2 can be treated
CC by administering an antagonist of PIGR-2, an antisense nucleic acid
CC molecule which inhibits the expression of PIGR-2 or administering
CC sufficient PIGR-2 to compete with the endogenous activity. PIGR-2 can be
CC used to identify its agonists by contacting a cell expressing PIGR-2 with
CC a candidate compound in the presence of a signal system and noting the
CC candidate as an agonist if a signal is produced. The same method can be
CC used to identify antagonists of PIGR-2 but the presence of an antagonist
CC is indicated by a decrease in production of the signal. Antibodies
CC against PIGR-2 may be used to isolate or identify clones expressing PIGR-
CC 2
XX
SQ Sequence 205 AA;

  Query Match   100.0%; Score 1108; DB 2; Length 205;
  Best Local Similarity 100.0%; Pred. No. 2.2e-95;
  Matches 205; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 MWLLPALLLLCLSGCLSLKGPGSVTGTAGDSLTVWCQYESMYKGYNKYWCRGQYDTSCES 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MWLLPALLLLCLSGCLSLKGPGSVTGTAGDSLTVWCQYESMYKGYNKYWCRGQYDTSCES 60

Qy         61 IVETKGEEKVERNGRVSIRDHPEALAFTVTMQNLNEDDAGSYWCKIQTVWVLDSWSRDPS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 IVETKGEEKVERNGRVSIRDHPEALAFTVTMQNLNEDDAGSYWCKIQTVWVLDSWSRDPS 120

Qy        121 DLVRVYVSPAITTPRRTTHPATPPIFLVVNPGRNLSTREVLTQNSGFRLSSPHFLVVLL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 DLVRVYVSPAITTPRRTTHPATPPIFLVVNPGRNLSTREVLTQNSGFRLSSPHFLVVLL 180
```

```
Qy        181 KLPLLLSMLGAVFWVNRPQWAPPGR 205
              |||||||||||||||||||||||||
Db        181 KLPLLLSMLGAVFWVNRPQWAPPGR 205
```

<!--EndFragment-->